Open AccessBurosumab for Pediatric X-Linked Hypophosphatemia
Author(s) -
Erik A. Imel
Publication year - 2021
Publication title -
current osteoporosis reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.472
H-Index - 57
eISSN - 1544-2241
pISSN - 1544-1873
DOI - 10.1007/s11914-021-00669-9
Subject(s) - hypophosphatemia , medicine , pediatrics , family medicine
X-Linked hypophosphatemia (XLH) is the most common genetic cause of rickets. This review describes advances in the management of XLH using burosumab which was FDA approved for treating children with XLH in 2018.